公开(公告)号：US06340476B1

公开(公告)日：2002-01-22

申请号：US09544732

申请日：2000-04-06

申请人： Kamal K. Midha ,  Theodore L. Iorio ,  Shubha Chungi

发明人： Kamal K. Midha ,  Theodore L. Iorio ,  Shubha Chungi

IPC分类号： A61K926

CPC分类号： A61K31/485 ,  A61K9/1676 ,  A61K9/2009 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/2081 ,  A61K9/2853 ,  A61K9/4808 ,  A61K9/5078 ,  A61K9/5084 ,  A61K31/435 ,  A61K31/44 ,  A61K31/4458 ,  A61K45/06 ,  A61K2300/00

摘要： Novel pharmaceutical dosage forms provide for pulsatile delivery of methylphenidate, i.e., release encapsulated drug in spaced apart “pulses.” The dosage forms are comprised of first, second and optionally third dosage units, with each dosage unit having a different drug release profile. The dosage forms may comprise capsules housing compressed tablets or drug-containing beads or particles, or may comprise a single tablet with the first, second and optionally third dosage units each representing an integral and discrete segment thereof. Methods of treatment using the pharmaceutical dosage forms are provided as well.

公开(公告)号：US20080145318A1

公开(公告)日：2008-06-19

申请号：US11610330

申请日：2006-12-13

申请人： Kamal K. Midha

发明人： Kamal K. Midha

IPC分类号： A61K31/135 ,  A61K31/439 ,  A61K9/70 ,  A61K9/12

CPC分类号： A61K31/135 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/4875 ,  A61K9/7061 ,  A61K31/439

摘要： Methods and formulations for delivering atomoxetine compounds that minimize drug metabolism and thus increase the effectiveness of the drug are disclosed. The in vivo potency of the atomoxetine compound may be maximized by minimizing the in vivo conversion of the atomoxetine compound to an atomoxetine compound metabolite.

摘要翻译： 公开了用于递送阿托莫西汀化合物的方法和制剂，其最小化药物代谢并因此增加药物的有效性。 通过最小化阿托莫西汀化合物与阿托西汀化合物代谢物的体内转化，可以使阿托莫西汀化合物的体内效力最大化。

公开(公告)号：US20080031932A1

公开(公告)日：2008-02-07

申请号：US11499912

申请日：2006-08-04

申请人： Kamal K. Midha

发明人： Kamal K. Midha

IPC分类号： A61K31/138 ,  A61K9/70

CPC分类号： A61K9/7061 ,  A61K9/06 ,  A61K31/138

摘要： Methods and formulations for delivering atomoxetine compounds that minimize drug metabolism and thus increase the effectiveness of the drug are disclosed. The method may include maximizing the in vivo potency of an atomoxetine compound in a subject by transdermally administering the atomoxetine compound to the subject. The in vivo potency of the atomoxetine compound may be maximized by minimizing the in vivo conversion of the atomoxetine compound to an atomoxetine compound metabolite.

摘要翻译： 公开了用于递送阿托莫西汀化合物的方法和制剂，其最小化药物代谢并因此增加药物的有效性。 该方法可以包括通过向受试者透皮施用阿托莫西汀化合物来最大化受试者中阿托莫西汀化合物的体内效力。 通过最小化阿托莫西汀化合物与阿托西汀化合物代谢物的体内转化，可以使阿托莫西汀化合物的体内效力最大化。